Atea Pharmaceuticals (AVIR) Competitors $3.67 -0.11 (-2.91%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.74 +0.07 (+2.02%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. CVAC, CALT, GPCR, HROW, PAHC, ABCL, NTLA, AMPH, WVE, and AUPHShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Intellia Therapeutics (NTLA), Amphastar Pharmaceuticals (AMPH), WAVE Life Sciences (WVE), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Harrow Phibro Animal Health AbCellera Biologics Intellia Therapeutics Amphastar Pharmaceuticals WAVE Life Sciences Aurinia Pharmaceuticals Atea Pharmaceuticals (NASDAQ:AVIR) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Which has more volatility and risk, AVIR or CVAC? Atea Pharmaceuticals has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500. Do analysts prefer AVIR or CVAC? Atea Pharmaceuticals presently has a consensus price target of $6.00, indicating a potential upside of 63.49%. CureVac has a consensus price target of $6.83, indicating a potential upside of 25.15%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Atea Pharmaceuticals is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has better valuation & earnings, AVIR or CVAC? CureVac has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea PharmaceuticalsN/AN/A-$168.38M-$1.65-2.22CureVac$579.18M2.11$175.50M$0.925.93 Is AVIR or CVAC more profitable? CureVac has a net margin of 35.44% compared to Atea Pharmaceuticals' net margin of 0.00%. CureVac's return on equity of 30.89% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -31.26% -29.27% CureVac 35.44%30.89%25.54% Do insiders and institutionals believe in AVIR or CVAC? 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 18.1% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer AVIR or CVAC? In the previous week, Atea Pharmaceuticals and Atea Pharmaceuticals both had 2 articles in the media. Atea Pharmaceuticals' average media sentiment score of 1.81 beat CureVac's score of 1.06 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CureVac 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCureVac beats Atea Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$323.49M$2.96B$5.61B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-2.2220.8528.1820.27Price / SalesN/A289.80428.6998.03Price / CashN/A42.8637.4658.16Price / Book0.717.638.045.49Net Income-$168.38M-$55.05M$3.19B$250.45M7 Day PerformanceN/A8.43%3.62%4.79%1 Month Performance14.33%5.42%4.06%7.68%1 Year Performance7.00%2.03%30.00%16.43% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals2.7409 of 5 stars$3.67-2.9%$6.00+63.5%+8.9%$323.49MN/A-2.2270News CoveragePositive NewsCVACCureVac4.6868 of 5 stars$5.41-0.7%$6.83+26.3%+67.0%$1.22B$579.18M5.88880Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.6096 of 5 stars$18.73-8.0%$76.17+306.7%-55.5%$1.17BN/A-21.53136HROWHarrow2.2111 of 5 stars$31.36-1.2%$61.40+95.8%+47.1%$1.16B$199.61M-56.00180News CoverageAnalyst ForecastPAHCPhibro Animal Health4.0544 of 5 stars$29.90+6.8%$24.40-18.4%+76.0%$1.13B$1.02B38.331,940High Trading VolumeABCLAbCellera Biologics2.4544 of 5 stars$4.03+6.1%$7.50+86.1%+28.1%$1.13B$28.83M-7.20500News CoverageAnalyst RevisionHigh Trading VolumeNTLAIntellia Therapeutics4.3511 of 5 stars$10.25-4.6%$33.37+225.5%-53.2%$1.11B$57.88M-1.96600AMPHAmphastar Pharmaceuticals4.3376 of 5 stars$22.86-1.5%$32.33+41.4%-44.7%$1.09B$731.97M8.282,028WVEWAVE Life Sciences4.5508 of 5 stars$7.06+1.6%$20.50+190.4%+29.8%$1.08B$108.30M-8.40240AUPHAurinia Pharmaceuticals3.0577 of 5 stars$7.47-1.6%$11.50+53.9%+50.2%$1.03B$235.13M26.68300Positive News Related Companies and Tools Related Companies CureVac Alternatives Calliditas Therapeutics AB (publ) Alternatives Structure Therapeutics Alternatives Harrow Alternatives Phibro Animal Health Alternatives AbCellera Biologics Alternatives Intellia Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives WAVE Life Sciences Alternatives Aurinia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
